Next Article in Journal
Telomerase-Targeted Cancer Immunotherapy
Previous Article in Journal
Anti-Apoptotic Effects of Recombinant Human Hepatocyte Growth Factor on Hepatocytes Were Associated with Intrahepatic Hemorrhage Suppression Indicated by the Preservation of Prothrombin Time
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2019, 20(8), 1822; https://doi.org/10.3390/ijms20081822

An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer

1
Faculty of Biology, Hanoi National University of Education, Hanoi 100000, Vietnam
2
School of Odonto Stomatology, Hanoi Medical University, Hanoi 100000, Vietnam
3
Institute of Cancer Research, Oslo University Hospital, 0372 Oslo, Norway
4
Department of Education and Training, Vietnam Military Medical University, Hanoi 100000, Vietnam
5
National Food Institute, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
6
Institute of Orthopaedics and Trauma Surgery, Viet Duc Hospital, Hanoi 100000, Vietnam
7
Institute for Research and Development, Duy Tan University, 03 Quang Trung, Danang 550000, Vietnam
8
AI Lab, Faculty of Information Technology, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam
9
Organ Transplantation Center, Viet Duc Hospital, Hanoi 100000, Vietnam
10
Faculty of Odonto-Stomatology, University of Medicine and Pharmacy, Ho Chi Minh City 700000, Vietnam
*
Authors to whom correspondence should be addressed.
They contributed equally to this manuscript.
Received: 8 March 2019 / Revised: 5 April 2019 / Accepted: 10 April 2019 / Published: 12 April 2019
(This article belongs to the Section Molecular Immunology)
  |  
PDF [697 KB, uploaded 18 April 2019]
  |  

Abstract

The selective expression of CD137 on cells of the immune system (e.g., T and DC cells) and oncogenic cells in several types of cancer leads this molecule to be an attractive target to discover cancer immunotherapy. Therefore, specific antibodies against CD137 are being studied and developed aiming to activate and enhance anti-cancer immune responses as well as suppress oncogenic cells. Accumulating evidence suggests that anti-CD137 antibodies can be used separately to prevent tumor in some cases, while in other cases, these antibodies need to be co-administered with other antibodies or drugs/vaccines/regents for a better performance. Thus, in this work, we aim to update and discuss current knowledge about anti-cancer effects of anti-CD137 antibodies as mono- and combined-immunotherapies. View Full-Text
Keywords: CD137/4-1BB; CD137L/4-1BBL; anti-CD137 antibodies; cancer immunotherapies; anti-CD137 antibody therapy CD137/4-1BB; CD137L/4-1BBL; anti-CD137 antibodies; cancer immunotherapies; anti-CD137 antibody therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Chu, D.-T.; Bac, N.D.; Nguyen, K.-H.; Tien, N.L.B.; Thanh, V.V.; Nga, V.T.; Ngoc, V.T.N.; Anh Dao, D.T.; Hoan, L.N.; Hung, N.P.; Trung Thu, N.T.; Pham, V.-H.; Vu, L.N.; Pham, T.A.V.; Thimiri Govinda Raj, D.B. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. Int. J. Mol. Sci. 2019, 20, 1822.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top